HBM Holdings Limited (HKG:2142)

Market Cap	9.13B -16.5%
Revenue (ttm)	1.40B +54.8%
Net Income	662.61M +15.6%
EPS	0.80 +13.3%
Shares Out	825.60M
PE Ratio	13.76
Forward PE	14.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,742,000
Open	11.06
Previous Close	10.74
Day's Range	10.94 - 11.20
52-Week Range	9.28 - 17.07
Beta	1.63
Analysts	Strong Buy
Price Target	24.01 (+117.09%)
Est. Earnings	Nov 27, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 327
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD

Analyst Summary

According to 3 analysts, the average rating for 2142 stock is "Strong Buy." The 12-month stock price target is $24.01, which is an increase of 117.09% from the latest price.

Price Target

$24.01

(117.09% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error